{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:46:38Z","timestamp":1787957198384,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Research Fund for Clinical Pharmacy of China International Medical Foundation","award":["Z-2021-46-2101"],"award-info":[{"award-number":["Z-2021-46-2101"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973289"],"award-info":[{"award-number":["81973289"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To update and assess the efficacy and tolerability of once weekly subcutaneous semaglutide in patients with type 2 diabetes (T2D).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>PubMed, Science Direct, Cochrane Library, Clinical trial, Springer, OVID, China National Knowledge Infrastructure (CNKI), WanFang Data and China Science and Technology Journal Database (VIP) were searched from inception to January 18, 2023. Randomized controlled trials (RCTs) comparing subcutaneous semaglutide with placebo or any other antidiabetic agent in adults with T2D were eligible. The risk ratio (RR) and mean difference (MD) with 95% confidence intervals (CIs) were determined to synthesize the results.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 17 trials enrolling 14,940 T2D patients were included. For efficacy, compared with placebo, semaglutide exhibited beneficial effects on glycosylated hemoglobin A1c (HbA1c) control [MD -0.97%, 95% CI (-1.33, -0.62), <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u200991%; MD -1.36%, 95% CI (-1.59, -1.13), <jats:italic>I<\/jats:italic><jats:sup><jats:italic>2<\/jats:italic><\/jats:sup>\u2009=\u200984%, semaglutide 0.5 and 1.0\u00a0mg, respectively], body weight reduction, blood pressure control. At the same time, subcutaneous semaglutide 0.5 and 1\u00a0mg reduced HbA<jats:sub>1c<\/jats:sub> by 0.56% (95% CI 0.32 to 0.80) and 0.63% (95% CI 0.35 to 0.91) compared to other glucose-lowering agents. For tolerability, semaglutide did not increase the incidence of adverse events (AEs) and serious adverse events (SAEs), severe or blood glucose (BG) confirmed hypoglycaemia, acute pancreatitis and diabetic retinopathy compared to placebo or active comparators, but did increase the risk of nausea, diarrhea and vomiting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Semaglutide has a better effect on glycaemic control and weight loss than other therapies. Nevertheless, semaglutide was associated with increased incidence of gastrointestinal-related disorders. Further large, multicenter randomized controlled clinical trials are still needed to obtain more robust evidence to better guide clinical treatment decisions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-023-01195-7","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:24:08Z","timestamp":1698463448000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis"],"prefix":"10.1186","volume":"15","author":[{"given":"Shanshan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guorong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"issue":"2","key":"1195_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1111\/joim.13049","volume":"288","author":"LING C","year":"2020","unstructured":"LING C. Epigenetic regulation of insulin action and secretion - role in the pathogenesis of type 2 Diabetes [J]. J Intern Med. 2020;288(2):158\u201367.","journal-title":"J Intern Med"},{"issue":"12","key":"1195_CR2","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"MJ DAVIES","year":"2018","unstructured":"DAVIES MJ, D\u2019ALESSIO D A, FRADKIN J, et al. Management of hyperglycemia in type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J]. Diabetes Care. 2018;41(12):2669\u2013701.","journal-title":"Diabetes Care"},{"issue":"12","key":"1195_CR3","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","volume":"65","author":"MJ DAVIES","year":"2022","unstructured":"DAVIES MJ, ARODA V R, COLLINS B S, et al. Management of hyperglycaemia in type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) [J]. Diabetologia. 2022;65(12):1925\u201366.","journal-title":"Diabetologia"},{"issue":"15","key":"1195_CR4","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1001\/jama.2019.2941","volume":"321","author":"HIRSCH I B","year":"2019","unstructured":"HIRSCH I B. The future of the GLP-1 receptor agonists [J]. JAMA. 2019;321(15):1457\u20138.","journal-title":"JAMA"},{"key":"1195_CR5","doi-asserted-by":"crossref","unstructured":"WHARTON S, CALANNA S, DAVIES M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4\u00a0mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss [J]. Volume 24. Diabetes, obesity & metabolism; 2022. pp. 94\u2013105. 1.","DOI":"10.1111\/dom.14551"},{"issue":"10","key":"1195_CR6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1001\/jamacardio.2020.1966","volume":"5","author":"HONIGBERG M C","year":"2020","unstructured":"HONIGBERG M C, CHANG L S, MCGUIRE D K, et al. Use of Glucagon-Like Peptide-1 receptor agonists in patients with type 2 Diabetes and Cardiovascular Disease: a review [J]. JAMA Cardiol. 2020;5(10):1182\u201390.","journal-title":"JAMA Cardiol"},{"issue":"1","key":"1195_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ DRUCKER","year":"2016","unstructured":"DRUCKER DJ. The Cardiovascular Biology of Glucagon-like Peptide-1 [J]. Cell Metabol. 2016;24(1):15\u201330.","journal-title":"Cell Metabol"},{"issue":"3","key":"1195_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s12020-018-1708-z","volume":"62","author":"X LI","year":"2018","unstructured":"LI X, WANG QIES. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 Diabetes Mellitus: a systemic review and meta-analysis [J]. Endocrine. 2018;62(3):535\u201345.","journal-title":"Endocrine"},{"key":"1195_CR9","doi-asserted-by":"crossref","unstructured":"ANDREADIS P, KARAGIANNIS T, MALANDRIS K, et al. Semaglutide for type 2 Diabetes Mellitus: a systematic review and meta-analysis [J]. Volume 20. Diabetes, obesity & metabolism; 2018. pp. 2255\u201363. 9.","DOI":"10.1111\/dom.13361"},{"key":"1195_CR10","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3389\/fphar.2018.00576","volume":"9","author":"H SHI F H, LI","year":"2018","unstructured":"SHI F H, LI H, CUI M, et al. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 Diabetes: a systematic review and Meta-analysis of Randomized Controlled trials [J]. Front Pharmacol. 2018;9:576.","journal-title":"Front Pharmacol"},{"key":"1195_CR11","doi-asserted-by":"crossref","unstructured":"MISHRIKY B M, CUMMINGS D M POWELLJR, et al. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 Diabetes: a systematic review and meta-analysis [J]. Volume 45. Diabetes & metabolism; 2019. pp. 102\u20139. 2.","DOI":"10.1016\/j.diabet.2018.09.002"},{"issue":"9","key":"1195_CR12","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.2337\/dc17-2381","volume":"41","author":"LINGVAY I","year":"2018","unstructured":"LINGVAY I, DESOUZA C V, LALIC K S, et al. A 26-Week randomized controlled trial of Semaglutide once Daily Versus Liraglutide and Placebo in patients with type 2 Diabetes suboptimally controlled on Diet and Exercise with or without metformin [J]. Diabetes Care. 2018;41(9):1926\u201337.","journal-title":"Diabetes Care"},{"key":"1195_CR13","doi-asserted-by":"crossref","unstructured":"ZINMAN B, BUSCH BHOSEKARV. R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 Diabetes (SUSTAIN 9): a randomised, placebo-controlled trial [J]. Volume 7. The lancet Diabetes & endocrinology; 2019. pp. 356\u201367. 5.","DOI":"10.1016\/S2213-8587(19)30066-X"},{"key":"1195_CR14","doi-asserted-by":"crossref","unstructured":"CAPEHORN MS, CATARIG A M FURBERGJK, et al. Efficacy and safety of once-weekly semaglutide 1.0\u00a0mg vs once-daily liraglutide 1.2\u00a0mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10) [J]. Volume 46. Diabetes & metabolism; 2020. pp. 100\u20139. 2.","DOI":"10.1016\/j.diabet.2019.101117"},{"key":"1195_CR15","doi-asserted-by":"crossref","unstructured":"JI L, DONG X, LI Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 Diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial [J]. Volume 23. Diabetes, obesity & metabolism; 2021. pp. 404\u201314. 2.","DOI":"10.1111\/dom.14232"},{"issue":"6","key":"1195_CR16","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP FR\u00edAS","year":"2021","unstructured":"FR\u00edAS JP, DAVIES M J, ROSENSTOCK J, et al. Tirzepatide versus Semaglutide once Weekly in patients with type 2 Diabetes [J]. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"5","key":"1195_CR17","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.diabet.2018.12.001","volume":"45","author":"ARODAVR AHMANN","year":"2019","unstructured":"AHMANN ARODAVR, CARIOU A. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 Diabetes: insights from the SUSTAIN 1\u20137 trials [J]. Diabetes Metab. 2019;45(5):409\u201318.","journal-title":"Diabetes Metab"},{"key":"1195_CR18","doi-asserted-by":"crossref","unstructured":"PAGE M J, MCKENZIE J E, BOSSUYT P M et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews [J]. BMJ (Clinical research ed), 2021, 372: n71.","DOI":"10.1136\/bmj.n71"},{"key":"1195_CR19","first-page":"n160","volume":"372","author":"MJ PAGE","year":"2021","unstructured":"PAGE MJ, BOSSUYT P MOHERD. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews [J]. BMJ (Clinical Research ed). 2021;372:n160.","journal-title":"BMJ (Clinical Research ed)"},{"key":"1195_CR20","first-page":"l4898","volume":"366","author":"J STERNE J A C, SAVOVI\u0106","year":"2019","unstructured":"STERNE J A C, SAVOVI\u0106 J, PAGE M J, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials [J]. BMJ (Clinical Research ed). 2019;366:l4898.","journal-title":"BMJ (Clinical Research ed)"},{"issue":"2","key":"1195_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"M AHMANN A J, CAPEHORN","year":"2018","unstructured":"AHMANN A J, CAPEHORN M, CHARPENTIER G, et al. Efficacy and safety of once-weekly Semaglutide Versus Exenatide ER in subjects with type 2 Diabetes (SUSTAIN 3): a 56-Week, Open-Label, Randomized Clinical trial [J]. Diabetes Care. 2018;41(2):258\u201366.","journal-title":"Diabetes Care"},{"key":"1195_CR22","doi-asserted-by":"crossref","unstructured":"AHR\u00e9N B, MASMIQUEL L, KUMAR H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 Diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial [J]. Volume 5. The lancet Diabetes & endocrinology; 2017. pp. 341\u201354. 5.","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"1195_CR23","doi-asserted-by":"crossref","unstructured":"ARODA V R, BAIN S C CARIOUB, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 Diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial [J]. Volume 5. The lancet Diabetes & endocrinology; 2017. pp. 355\u201366. 5.","DOI":"10.1016\/S2213-8587(17)30085-2"},{"issue":"15","key":"1195_CR24","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","volume":"318","author":"M DAVIES","year":"2017","unstructured":"DAVIES M, PIEBER T R, HARTOFT-NIELSEN M, L, et al. Effect of oral Semaglutide compared with placebo and Subcutaneous Semaglutide on Glycemic Control in patients with type 2 Diabetes: a randomized clinical trial [J]. JAMA. 2017;318(15):1460\u201370.","journal-title":"JAMA"},{"key":"1195_CR25","doi-asserted-by":"crossref","unstructured":"KAKU K, YAMADA Y, WATADA H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic Drugs in Japanese people with inadequately controlled type 2 Diabetes: a randomized trial [J]. Volume 20. Diabetes, obesity & metabolism; 2018. pp. 1202\u201312. 5.","DOI":"10.1111\/dom.13218"},{"key":"1195_CR26","doi-asserted-by":"crossref","unstructured":"LINGVAY I, CATARIG A M, FRIAS JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 Diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial [J]. Volume 7. The lancet Diabetes & endocrinology; 2019. pp. 834\u201344. 11.","DOI":"10.1016\/S2213-8587(19)30311-0"},{"issue":"19","key":"1195_CR27","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"CONSOLIA MARSO S P, BAIN S C","year":"2016","unstructured":"MARSO S P, BAIN S C CONSOLIA, et al. Semaglutide and Cardiovascular outcomes in patients with type 2 Diabetes [J]. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"2","key":"1195_CR28","doi-asserted-by":"publisher","first-page":"231","DOI":"10.2337\/dc15-0165","volume":"39","author":"G NAUCK M A, PETRIE J R, SESTI","year":"2016","unstructured":"NAUCK M A, PETRIE J R, SESTI G, et al. A phase 2, Randomized, dose-finding study of the Novel once-Weekly Human GLP-1 Analog, Semaglutide, compared with placebo and open-label liraglutide in patients with type 2 Diabetes [J]. Diabetes Care. 2016;39(2):231\u201341.","journal-title":"Diabetes Care"},{"key":"1195_CR29","doi-asserted-by":"crossref","unstructured":"PRATLEY R E, ARODA V R, LINGVAY I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 Diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial [J]. Volume 6. The lancet Diabetes & endocrinology; 2018. pp. 275\u201386. 4.","DOI":"10.1016\/S2213-8587(18)30024-X"},{"issue":"6","key":"1195_CR30","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"I RODBARD H W, LINGVAY","year":"2018","unstructured":"RODBARD H W, LINGVAY I, REED J, et al. Semaglutide added to basal insulin in type 2 Diabetes (SUSTAIN 5): a Randomized, controlled trial [J]. J Clin Endocrinol Metab. 2018;103(6):2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"1195_CR31","doi-asserted-by":"crossref","unstructured":"SEINO Y, TERAUCHI Y, OSONOI T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 Diabetes [J]. Volume 20. Diabetes, obesity & metabolism; 2018. pp. 378\u201388. 2.","DOI":"10.1111\/dom.13082"},{"key":"1195_CR32","doi-asserted-by":"crossref","unstructured":"SORLI C, HARASHIMA S I, TSOUKAS G M, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 Diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial [J]. Volume 5. The lancet Diabetes & endocrinology; 2017. pp. 251\u201360. 4.","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"1195_CR33","doi-asserted-by":"crossref","unstructured":"GLOYN A L, DRUCKER D J. Precision medicine in the management of type 2 Diabetes [J]. Volume 6. The lancet Diabetes & endocrinology; 2018. pp. 891\u2013900. 11.","DOI":"10.1016\/S2213-8587(18)30052-4"},{"issue":"1","key":"1195_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"NATHAN D M","year":"2014","unstructured":"NATHAN D M. The Diabetes control and Complications trial\/epidemiology of Diabetes interventions and Complications study at 30 years: overview [J]. Diabetes Care. 2014;37(1):9\u201316.","journal-title":"Diabetes Care"},{"key":"1195_CR35","doi-asserted-by":"crossref","unstructured":"Effect of intensive. Blood-glucose control with metformin on Complications in overweight patients with type 2 Diabetes (UKPDS 34). UK prospective Diabetes study (UKPDS) Group [J]. Lancet (London, England), 1998, 352(9131): 854\u201365.","DOI":"10.1016\/S0140-6736(98)07037-8"},{"issue":"10","key":"1195_CR36","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1001\/jamaneurol.2020.1512","volume":"77","author":"LIOUTAS V A","year":"2020","unstructured":"LIOUTAS V A, BEISER A S, APARICIO H J, et al. Assessment of incidence and risk factors of Intracerebral Hemorrhage among participants in the Framingham Heart Study between 1948 and 2016 [J]. JAMA Neurol. 2020;77(10):1252\u201360.","journal-title":"JAMA Neurol"},{"issue":"8","key":"1195_CR37","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS VIRANI","year":"2021","unstructured":"VIRANI SS, APARICIO H J ALONSOA, et al. Heart Disease and Stroke Statistics-2021 update: a Report from the American Heart Association [J]. Circulation. 2021;143(8):e254\u2013e743.","journal-title":"Circulation"},{"key":"1195_CR38","doi-asserted-by":"crossref","unstructured":"RUEGSEGGER G N, VANDERBOOM P M, DASARI S et al. Exercise and metformin counteract altered mitochondrial function in the insulin-resistant brain [J]. JCI insight, 2019, 4(18).","DOI":"10.1172\/jci.insight.130681"},{"key":"1195_CR39","doi-asserted-by":"crossref","unstructured":"HA MS, LEE J H, JEONG W M et al. The combined intervention of Aqua Exercise and Burdock Extract synergistically improved arterial stiffness: a Randomized, Double-Blind, controlled trial [J]. Metabolites, 2022, 12(10).","DOI":"10.3390\/metabo12100970"},{"issue":"18","key":"1195_CR40","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR LUNDGREN","year":"2021","unstructured":"LUNDGREN JR, JANUS C, JENSEN S B K, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or both combined [J]. N Engl J Med. 2021;384(18):1719\u201330.","journal-title":"N Engl J Med"},{"issue":"10148","key":"1195_CR41","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"B O\u2019NEIL P M, BIRKENFELD A L, MCGOWAN","year":"2018","unstructured":"O\u2019NEIL P M, BIRKENFELD A L, MCGOWAN B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial [J]. Lancet (London England). 2018;392(10148):637\u201349.","journal-title":"Lancet (London England)"},{"issue":"8","key":"1195_CR42","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/ckj\/sfac096","volume":"15","author":"AVILES BUENO B","year":"2022","unstructured":"AVILES BUENO B, SOLER M J, PEREZ-BELMONTE L, et al. Semaglutide in type 2 Diabetes with chronic Kidney Disease at high risk progression-real-world clinical practice [J]. Clin Kidney J. 2022;15(8):1593\u2013600.","journal-title":"Clin Kidney J"},{"issue":"10278","key":"1195_CR43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M DAVIES","year":"2021","unstructured":"DAVIES M, F\u00e6RCH L, JEPPESEN O K, et al. Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 Diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial [J]. Lancet (London England). 2021;397(10278):971\u201384.","journal-title":"Lancet (London England)"},{"issue":"14","key":"1195_CR44","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D RUBINO","year":"2021","unstructured":"RUBINO D, ABRAHAMSSON N, DAVIES M, et al. Effect of continued Weekly Subcutaneous Semaglutide vs Placebo on Weight loss maintenance in adults with overweight or obesity: the STEP 4 Randomized Clinical trial [J]. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"14","key":"1195_CR45","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"WADDEN T A","year":"2021","unstructured":"WADDEN T A, BAILEY T S, BILLINGS L K, et al. Effect of Subcutaneous Semaglutide vs Placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 Randomized Clinical trial [J]. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"11","key":"1195_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"S WILDING J P H, BATTERHAM R L, CALAN","year":"2021","unstructured":"WILDING J P H, BATTERHAM R L, CALANNA S, et al. Once-weekly semaglutide in adults with overweight or obesity [J]. N Engl J Med. 2021;384(11):989.","journal-title":"N Engl J Med"},{"issue":"1","key":"1195_CR47","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12933-020-01106-4","volume":"19","author":"M HUSAIN","year":"2020","unstructured":"HUSAIN M, BAIN S C, HOLST A G, et al. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials [J]. Cardiovasc Diabetol. 2020;19(1):156.","journal-title":"Cardiovasc Diabetol"},{"key":"1195_CR48","doi-asserted-by":"crossref","unstructured":"RAKIPOVSKI G, ROLIN B, N\u00f8HR J et al. The GLP-1 analogs Liraglutide and Semaglutide reduce Atherosclerosis in ApoE(-\/-) and LDLr(-\/-) mice by a mechanism that includes inflammatory pathways [J]. JACC Basic to translational science, 2018, 3(6): 844\u201357.","DOI":"10.1016\/j.jacbts.2018.09.004"},{"key":"1195_CR49","doi-asserted-by":"crossref","unstructured":"SUN F, CHAI S, YU K, et al. Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 Diabetes: a systematic review and network meta-analysis [J]. Volume 17. Diabetes technology & therapeutics; 2015. pp. 35\u201342. 1.","DOI":"10.1089\/dia.2014.0188"},{"issue":"12","key":"1195_CR50","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1007\/s001250050613","volume":"39","author":"MA NAUCK","year":"1996","unstructured":"NAUCK MA, WOLLSCHL\u00e4GER D, WERNER J, et al. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7\u201336 amide]) in patients with NIDDM [J]. Diabetologia. 1996;39(12):1546\u201353.","journal-title":"Diabetologia"},{"issue":"1","key":"1195_CR51","doi-asserted-by":"publisher","first-page":"T1","DOI":"10.1530\/JOE-13-0414","volume":"221","author":"VAN BLOEMENDAAL L","year":"2014","unstructured":"VAN BLOEMENDAAL L, TEN KULVE J S, LA FLEUR S E, et al. Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS [J]. J Endocrinol. 2014;221(1):T1\u201316.","journal-title":"J Endocrinol"},{"issue":"2","key":"1195_CR52","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2337\/diacare.29.02.06.dc05-2043","volume":"29","author":"PS DENKER","year":"2006","unstructured":"DENKER PS, DIMARCO PE. Exenatide (exendin-4)-induced Pancreatitis: a case report [J]. Diabetes Care. 2006;29(2):471.","journal-title":"Diabetes Care"},{"key":"1195_CR53","first-page":"g2366","volume":"348","author":"L LI","year":"2014","unstructured":"LI L, SHEN J, BALA M M, et al. Incretin treatment and risk of Pancreatitis in patients with type 2 Diabetes Mellitus: systematic review and meta-analysis of randomised and non-randomised studies [J]. BMJ (Clinical Research ed). 2014;348:g2366.","journal-title":"BMJ (Clinical Research ed)"},{"issue":"2","key":"1195_CR54","doi-asserted-by":"publisher","first-page":"286","DOI":"10.2337\/dc17-0280","volume":"41","author":"M BONIOL","year":"2018","unstructured":"BONIOL M, FRANCHI M, BOTA M, et al. Incretin-based therapies and the short-term risk of Pancreatic Cancer: results from two retrospective cohort studies [J]. Diabetes Care. 2018;41(2):286\u201392.","journal-title":"Diabetes Care"},{"key":"1195_CR55","doi-asserted-by":"crossref","unstructured":"MONAMI M, NREU B, SCATENA A, et al. Safety issues with glucagon-like peptide-1 receptor agonists (Pancreatitis, Pancreatic cancer and cholelithiasis): data from randomized controlled trials [J]. Volume 19. Diabetes, obesity & metabolism; 2017. pp. 1233\u201341. 9.","DOI":"10.1111\/dom.12926"},{"key":"1195_CR56","doi-asserted-by":"crossref","unstructured":"STORGAARD H, COLD F. GLUUD L L, et al. Glucagon-like peptide-1 receptor agonists and risk of acute Pancreatitis in patients with type 2 Diabetes [J]. Volume 19. Diabetes, obesity & metabolism; 2017. pp. 906\u20138. 6.","DOI":"10.1111\/dom.12885"},{"issue":"11","key":"1195_CR57","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.2337\/dc17-2280","volume":"41","author":"A DOUROS","year":"2018","unstructured":"DOUROS A, FILION K B YINH, et al. Glucagon-like peptide 1 receptor agonists and the risk of Incident Diabetic retinopathy [J]. Diabetes Care. 2018;41(11):2330\u20138.","journal-title":"Diabetes Care"},{"key":"1195_CR58","doi-asserted-by":"crossref","unstructured":"WANG L, DING J, ZHU C et al. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole\u2013kindled mice [J]. Int J Mol Med, 2021, 48(6).","DOI":"10.3892\/ijmm.2021.5052"},{"key":"1195_CR59","doi-asserted-by":"publisher","first-page":"975830","DOI":"10.3389\/fphar.2023.975830","volume":"14","author":"X CHEN","year":"2023","unstructured":"CHEN X, CHEN S, LI Z, et al. Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice [J]. Front Pharmacol. 2023;14:975830.","journal-title":"Front Pharmacol"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01195-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:26:35Z","timestamp":1698463595000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01195-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1195"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01195-7","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"11 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"218"}}